

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
**(位元堂藥業控股有限公司\*)**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 897)**

**PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the Reporting Period and the information currently available to the Board, the Group is expected to record a decrease from a profit attributable to owners of the parent for the Corresponding Period of approximately HK\$23.7 million to a profit attributable to owners of the parent of not more than approximately HK\$3.0 million for the Reporting Period.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Wai Yuen Tong Medicine Holdings Limited (位元堂藥業控股有限公司\*) (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**” or the “**Directors**”) of the Company would like to inform the shareholders and potential investors of the Company that based on the preliminary review of the draft unaudited consolidated management accounts of the Group for the six months ended 30 September 2025 (the “**Reporting Period**”) and the information currently available to the Board, the Group is expected to record a decrease from a profit attributable to owners of the parent for the six months ended 30 September 2024 (the “**Corresponding Period**”) of approximately HK\$23.7 million to a profit attributable to owners of the parent of not more than approximately HK\$3.0 million for the Reporting Period.

Such expected decrease in profit is mainly attributable to the combined effect of:

- 1) a decrease of approximately 7% in revenue driven by weakened consumer sentiment in the retail market during the Reporting Period as compared to the Corresponding Period, which resulted in a drop in gross profit of the Group;
- 2) a significant decrease of net gains on disposal of properties during the Reporting Period; and
- 3) a reduction in net fair value gains on investment properties for the Reporting Period.

These impacts were partially offset by a decrease in administrative expenses and finance costs during the Reporting Period.

As the Company is still in the course of finalising its results for the Reporting Period, the information contained in this announcement is solely based on the preliminary assessment by the Board after reviewing the draft unaudited consolidated management accounts of the Group for the Reporting Period which have yet to be finalised. Details of the performance of the Group for the Reporting Period will be disclosed in the interim results announcement of the Company, which is expected to be published on or before the end of November 2025 in accordance with the requirements under the Listing Rules.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**WAI YUEN TONG MEDICINE HOLDINGS LIMITED**  
(位元堂藥業控股有限公司\*)  
**Tang Ching Ho**  
*Chairman and Managing Director*

Hong Kong, 17 November 2025

*As at the date of this announcement, the executive directors of the Company are Mr. Tang Ching Ho, Ms. Tang Wai Man and Ms. Law Man Yee, Anita, and the independent non-executive directors of the Company are Mr. Li Ka Fai, David, Professor Sit Wing Hang, and Professor Chan Wing Kwong.*

\* For identification purpose only